Stock Track | Braveheart Bio Soars 67.78% in Debut After Upsized $383 Million IPO

Stock Track

08/07

Shares of Braveheart Bio Inc. (BRVE) soared 67.78% during intraday trading on Thursday, marking a stellar debut on the Nasdaq Global Market.

The surge comes after the clinical-stage biopharmaceutical company priced its upsized initial public offering at $18 per share, the high end of its marketing range. The company sold approximately 21.3 million shares, raising $382.5 million in gross proceeds, after increasing the deal size from 18.75 million shares and pricing above the initial $15 to $17 range. The strong investor demand for the offering fueled the significant first-day pop.

Braveheart Bio is focused on developing therapies for patients with hypertrophic cardiomyopathy and other serious cardiovascular diseases. The company intends to use the IPO proceeds to advance the development of its lead product candidate, BHB‑1893.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1150536472"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1150536472\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1150536472?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 00:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150536472","market":"nz","top_or_hot":-1,"title":"Stock Track | Braveheart Bio Soars 67.78% in Debut After Upsized $383 Million IPO","media":"Stock Track","content":"<p>Shares of Braveheart Bio Inc. (BRVE) soared 67.78% during intraday trading on Thursday, marking a stellar debut on the Nasdaq Global Market.</p><p>The surge comes after the clinical-stage biopharmaceutical company priced its upsized initial public offering at $18 per share, the high end of its marketing range. The company sold approximately 21.3 million shares, raising $382.5 million in gross proceeds, after increasing the deal size from 18.75 million shares and pricing above the initial $15 to $17 range. The strong investor demand for the offering fueled the significant first-day pop.</p><p>Braveheart Bio is focused on developing therapies for patients with hypertrophic cardiomyopathy and other serious cardiovascular diseases. The company intends to use the IPO proceeds to advance the development of its lead product candidate, BHB‑1893.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Braveheart Bio Soars 67.78% in Debut After Upsized $383 Million IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Braveheart Bio Soars 67.78% in Debut After Upsized $383 Million IPO\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-08-07 00:52</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of Braveheart Bio Inc. (BRVE) soared 67.78% during intraday trading on Thursday, marking a stellar debut on the Nasdaq Global Market.</p><p>The surge comes after the clinical-stage biopharmaceutical company priced its upsized initial public offering at $18 per share, the high end of its marketing range. The company sold approximately 21.3 million shares, raising $382.5 million in gross proceeds, after increasing the deal size from 18.75 million shares and pricing above the initial $15 to $17 range. The strong investor demand for the offering fueled the significant first-day pop.</p><p>Braveheart Bio is focused on developing therapies for patients with hypertrophic cardiomyopathy and other serious cardiovascular diseases. The company intends to use the IPO proceeds to advance the development of its lead product candidate, BHB‑1893.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BRVE","symbol_name":"Braveheart Bio","start_time":0,"source_url":"","article_id":"1150536472","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150536472","pubTimestamp":1786035174,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Braveheart Bio Inc. (BRVE) soared 67.78% during intraday trading on Thursday, marking a stellar debut on the Nasdaq Global Market.The surge comes after the clinical-stage biopharmaceutical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BRVE":"Braveheart Bio"},"translate_title":"股票追踪 | Braveheart Bio 首次公开募股规模扩大 3.83 亿美元后，首日股价飙升 67.78%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BRVE":1},"content_text":"Shares of Braveheart Bio Inc. (BRVE) soared 67.78% during intraday trading on Thursday, marking a stellar debut on the Nasdaq Global Market.The surge comes after the clinical-stage biopharmaceutical company priced its upsized initial public offering at $18 per share, the high end of its marketing range. The company sold approximately 21.3 million shares, raising $382.5 million in gross proceeds, after increasing the deal size from 18.75 million shares and pricing above the initial $15 to $17 range. The strong investor demand for the offering fueled the significant first-day pop.Braveheart Bio is focused on developing therapies for patients with hypertrophic cardiomyopathy and other serious cardiovascular diseases. The company intends to use the IPO proceeds to advance the development of its lead product candidate, BHB‑1893.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}